News &amp; Updates

Taking diltiazem and direct oral anticoagulants (DOACs) together appears to contribute to increased bleeding risk in patients with atrial fibrillation (AF), regardless of the presence of chronic kidney disease, as shown in a study.

Concomitant diltiazem use with DOACs pose increased bleeding risk in AF

Medication disrupts human gut microbiome

Exposure to single or multiple drugs can have extensive disruptive effects on the human gut microbiome, a new study has found.

Medication disrupts human gut microbiome

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

16 Jul 2022 by

Second-line treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) led to significantly longer event-free survival (EFS) in patients aged ≥65 years with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) compared with standard of care (SoC), according to a preplanned subgroup analysis of the ZUMA-7** trial presented at EHA 2022.

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

Meta-analysis favours citalopram in poststroke recovery

15 Jul 2022 by

Selective serotonin reuptake inhibitors (SSRIs) can prevent and treat depression following stroke, in addition to improving anxiety, dependence, motor function, and cognitive function—benefits that are only reproducible with citalopram but not fluoxetine, according to a meta-analysis said to be the most up to date.

Meta-analysis favours citalopram in poststroke recovery

15 Jul 2022

GI practitioners cease PPI use in patients due to concerns of side effects

Discontinuation of proton pump inhibitor (PPI) use remains prevalent, even within a group of mostly academic gastroenterology (GI) practitioners, despite evidence suggesting the safety of long-term PPI use without routine monitoring, a study has shown.

GI practitioners cease PPI use in patients due to concerns of side effects

Concomitant azole use may influence bleeding risk in AF patients on NOACs

15 Jul 2022 by

In a study evaluating azole use in patients with atrial fibrillation (AF) on non-vitamin K antagonist oral anticoagulants (NOACs), systemic exposure to the antifungal agent fluconazole was associated with an elevated risk of bleeding, particularly among those on apixaban. Conversely, no association was seen between NOACs and topical azoles*.

Concomitant azole use may influence bleeding risk in AF patients on NOACs

Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD

Olaparib demonstrates clinical activity across patients with platinum-sensitive relapsed ovarian cancer and known BRCA mutation and homologous recombination deficiency (HRD), as shown in the phase II LIGHT study.

Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD

15 Jul 2022

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

14 Jul 2022 by

Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

14 Jul 2022

Aspirin use lowers risk of liver cancer

A recent study has shown that use of aspirin can help reduce the risk of developing liver cancer.

Aspirin use lowers risk of liver cancer

Antiplatelet drugs up bleeding, decompensation events in cirrhosis patients

Use of antiplatelet (AP) medication appears to increase bleeding and decompensation events among privately insured patients with cirrhosis, a study has found. Use of nonsteroidal anti-inflammatory drug (NSAID) is also associated with significant early bleeding, but not decompensations. Anticoagulants (AC), on the other hand, are not associated with bleeding or decompensation outcomes.

Antiplatelet drugs up bleeding, decompensation events in cirrhosis patients